Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US

Vaccine

Volumn 29, Issue 45, 2011, Pages 8042-8048

  Shea, K M ^a,b   Weycker, D ^c   Stevenson, A E ^b   Strutton, D R ^d   Pelton, S I ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c POLICY ANALYSIS INC PAI   (United States)

^d PFIZER INC   (United States)

Author keywords

Acute otitis media; Pneumococcal vaccine; Serotype replacement

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ARTICLE; BACTERIAL COLONIZATION; CHILD; DRUG EFFICACY; HUMAN; NASOPHARYNX; PNEUMOCOCCAL ACUTE OTITIS MEDIA; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION; VALIDATION STUDY;

CARRIER STATE; CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; MODELS, STATISTICAL; NASOPHARYNX; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 80053651129     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.057     Document Type: Article

References (39)

1. Black S., Lieu T.A., Ray G.T., Capra A., Shinefield H.R. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Vaccine 2000, 19(Suppl. 1):S83-S86.
2. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344(6):403-409.
3. Fireman B., Black S.B., Shinefield H.R., Lee J., Lewis E., Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22(1):10-16.
4. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
5. Grijalva C., Poehling K., Nuorti P., Zhu Y., Martin S., Edwards K., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118(3):865-873.
6. Poehling K., Szilagyi P., Grijalva C., Martin S., LaFleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007, 119(4):707-715.
7. Zhou F., Shefer A., Kong Y., Nuorti P. Trends in acute otitis media-related heath care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008, 121(2):253-260.
8. De Wals P., Carbon M., Sevin E., Deceuninck G., Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2009, 28(9):e271-e275.
9. Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., Bridges C.B. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-8):1-40.
10. McCaig L.F., Besser R.E., Hughes J.M. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002, 287(23):3096-3102.
11. Finkelstein J.A., Stille C., Nordin J., Davis R., Raebel M.A., Roblin D. Reduction in antibiotic use among US children, 1996-2000. Pediatrics 2003, 112(3):620-627.
12. Dowell S.F., Marcy S.M., Phillips W.R., Gerber M.A., Schwartz B. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics 1998, 101(1 Suppl.):163-165.
13. Dowell S.F., Marcy S.M., Phillips W.R., Gerber M.A., Schwartz B. Otitis media: principles of judicious use of antimicrobial agents. Pediatrics 1998, 101(1 Suppl.):165-171.
14. Pichichero M.E., Casey J.R. Acute otitis media disease management. Minerva Pediatr 2003, 55(5):415-438.
15. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005, 116(3):e408-e413.
16. Huang S.S., Hinrichsen V.L., Stevenson A.E., Rifas-Shiman S.L., Kleinman K., Pelton S.I., et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009, 124(1):e1-e11.
17. Casey J.R., Adlowitz D.G., Pichichero M.E. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010, 29(4):304-309.
18. Brueggemann A.B., Griffiths D.T., Meats E., Peto T., Crook D.W., Spratt B.G. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003, 187(9):1424-1432.
19. Hanage W.P., Kaijalainen T.H., Syrjanen R.K., Auranen K., Leinonen M., Makela P.H., et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun 2005, 73(1):431-435.
20. Yildirim I., Hanage W.P., Lipsitch M., Shea K.M., Stevenson A., Finkelstein J., et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, (October). [Epub ahead of print].
21. Hoberman A., Greenberg D.P., Paradise J.L., Rockette H.E., Lave J.R., Kearney D.H., et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003, 290(12):1608-1616.
22. Park I.H., Moore M.R., Treanor J.J., Pelton S.I., Pilishvili T., Beall B., et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008, 198(12):1818-1822.
23. Cooper D., Yu X., Sidhu M., Nahm M.H., Fernsten P., Jansen K.U. 13-Valent pneumococcal conjugate vaccine elicits strong opsonophagocytic killing (OPA) activity to streptococcus pneumoniae serotypes 6A, 6B, and 6C. Poster presentation at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD7) 2010.
24. Rubin J.L., McGarry L.J., Strutton D.R., Klugman K.P., Pelton S.I., Gilmore K.E., et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, (September). [Epub ahead of print].
25. Brueggemann A.B., Peto T.E., Crook D.W., Butler J.C., Kristinsson K.G., Spratt B.G. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004, 190(7):1203-1211.
26. Smith T., Lehmann D., Montgomery J., Gratten M., Riley I.D., Alpers M.P. Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children. Epidemiol Infect 1993, 111(1):27-39.
27. Sleeman K.L., Griffiths D., Shackley F., Diggle L., Gupta S., Maiden M.C., et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 2006, 194(5):682-688.
28. Shouval D.S., Greenberg D., Givon-Lavi N., Porat N., Dagan R. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 2006, 25(7):602-607.
29. Armitage P., Colton T. Encylclopedia of biostatistics 2005, John Wiley & Sons, Hoboken, NJ. 2nd ed.
30. The Center's for Disease Control and Prevention Active Bacterial Core Surveillance (ABCs) program (unpublished data 2000-2007) - provided by Matt Moore, MD.
31. Johnson C.E., Carlin S.A., Super D.M., Rehmus J.M., Roberts D.G., Christopher N.C., et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991, 119(1 Pt 1):117-122.
32. Luotonen J., Herva E., Karma P., Timonen M., Leinonen M., Makela P.H. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scand J Infect Dis 1981, 13(3):177-183.
33. Bluestone C.D., Stephenson J.S., Martin L.M. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992, 11(8 Suppl.):S7-S11.
34. Block S.L. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J 1997, 16(4):449-456.
35. Thompson P.L., Gilbert R.E., Long P.F., Saxena S., Sharland M., Wong I.C.K. Has UK guidance affected general practitioner antibiotic prescribing for otitis media in children?. J Public Health 2008, 30(4):479-486.
36. Hubner N.O., Hubner C., Wodny M., Kampf G., Kramer A. Effectiveness of alcohol-based hand disinfectants in a public administration: impact on health and work performance related to acute respiratory symptoms and diarrhea. BMC Infect Dis 2010, 10:250.
37. Pelton S.I., Huot H., Finkelstein J.A., Bishop C.J., Hsu K.K., Kellenberg J., et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26(6):468-472.
38. Centers for Disease Control and Prevention (CDC) Chapter 17: pneumococcal disease. Epidemiology and prevention of vaccine-preventable disease 2008, Public Health Foundation, Washington, DC. 10th ed. 2nd printing. W. Atkinson, J. Hamborsky, L. McIntyre, S. Wolfe (Eds.).
39. Hanage W.P., Auranen K., Syrjänen R., Herva E., Mäkelä P.H., Kilpi T., et al. Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun 2004, 72(January (1)):76-81.